X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs SUN PHARMA - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH SUN PHARMA STERLING BIOTECH/
SUN PHARMA
 
P/E (TTM) x -1.8 25.7 - View Chart
P/BV x 0.1 3.8 1.9% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 STERLING BIOTECH   SUN PHARMA
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
SUN PHARMA
Mar-17
STERLING BIOTECH/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs11842 1.2%   
Low Rs3572 0.6%   
Sales per share (Unadj.) Rs26.8131.6 20.4%  
Earnings per share (Unadj.) Rs-15.032.7 -45.7%  
Cash flow per share (Unadj.) Rs-5.538.0 -14.4%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs54.9152.7 35.9%  
Shares outstanding (eoy) m267.872,399.26 11.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.35.4 4.8%   
Avg P/E ratio x-0.521.6 -2.1%  
P/CF ratio (eoy) x-1.318.6 -6.8%  
Price / Book Value ratio x0.14.6 2.7%  
Dividend payout %010.7 0.0%   
Avg Mkt Cap Rs m1,8621,696,877 0.1%   
No. of employees `0001.417.5 7.7%   
Total wages/salary Rs m54749,023 1.1%   
Avg. sales/employee Rs Th5,303.318,028.3 29.4%   
Avg. wages/employee Rs Th403.82,798.8 14.4%   
Avg. net profit/employee Rs Th-2,959.04,479.5 -66.1%   
INCOME DATA
Net Sales Rs m7,181315,784 2.3%  
Other income Rs m436,232 0.7%   
Total revenues Rs m7,223322,016 2.2%   
Gross profit Rs m947100,893 0.9%  
Depreciation Rs m2,54312,648 20.1%   
Interest Rs m4,3773,998 109.5%   
Profit before tax Rs m-5,93190,479 -6.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,92412,116 -15.9%   
Profit after tax Rs m-4,00778,462 -5.1%  
Gross profit margin %13.231.9 41.3%  
Effective tax rate %32.413.4 242.3%   
Net profit margin %-55.824.8 -224.6%  
BALANCE SHEET DATA
Current assets Rs m14,335329,537 4.4%   
Current liabilities Rs m49,809178,870 27.8%   
Net working cap to sales %-494.047.7 -1,035.4%  
Current ratio x0.31.8 15.6%  
Inventory Days Days40379 510.7%  
Debtors Days Days17183 205.0%  
Net fixed assets Rs m55,432204,766 27.1%   
Share capital Rs m2682,399 11.2%   
"Free" reserves Rs m13,935363,997 3.8%   
Net worth Rs m14,701366,397 4.0%   
Long term debt Rs m9,47814,361 66.0%   
Total assets Rs m73,988614,102 12.0%  
Interest coverage x-0.423.6 -1.5%   
Debt to equity ratio x0.60 1,644.9%  
Sales to assets ratio x0.10.5 18.9%   
Return on assets %0.513.4 3.7%  
Return on equity %-27.321.4 -127.3%  
Return on capital %-6.424.8 -25.9%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,86044,118 4.2%   
Fx outflow Rs m2524,484 0.1%   
Net fx Rs m1,83519,634 9.3%   
CASH FLOW
From Operations Rs m1,71970,822 2.4%  
From Investments Rs m-3,148-42,216 7.5%  
From Financial Activity Rs m1,426-22,854 -6.2%  
Net Cashflow Rs m-36,107 -0.1%  

Share Holding

Indian Promoters % 33.9 63.7 53.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 5.1 -  
FIIs % 9.9 23.0 43.0%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 8.3 473.5%  
Shareholders   21,482 133,026 16.1%  
Pledged promoter(s) holding % 55.9 0.5 10,554.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   FULFORD INDIA  VENUS REMEDIES  PIRAMAL ENTERPRISES  WOCKHARDT LTD.  SUVEN LIFE  

Compare STERLING BIOTECH With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Tata Chem: Suspension of Haldia Operations Drag Bottomline Lower (Quarterly Results Update - Detailed)

Aug 17, 2017

Interruption at Haldia plant and fire at Lostock facility hits operations during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Jan 19, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH - IPCA LABS COMPARISON

COMPARE STERLING BIOTECH WITH

MARKET STATS